Holen Sie sich die Stockscreener-App
0.00
100.00%
-2.38
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt SAVA?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$2.38
Offen:
$0
24-Stunden-Volumen:
0
Relative Volume:
0.00
Marktkapitalisierung:
$114.97M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-97.22M
KGV:
0.00
EPS:
-1.38
Netto-Cashflow:
$-82.44M
1W Leistung:
-100.00%
1M Leistung:
-100.00%
6M Leistung:
-100.00%
1J Leistung:
-100.00%
1-Tages-Spanne:
$0.00
$0.00
1-Wochen-Bereich:
$0.00
$0.00
52-Wochen-Spanne:
$0.00
$4.98
Cassava Sciences Inc Stock (SAVA) Company Profile
Firmenname
Cassava Sciences Inc
Sektor
Branche
Telefon
512-501-2444
Adresse
6801 N CAPITAL OF TEXAS HIGHWAY, AUSTIN, TX
Compare SAVA vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SAVA
Cassava Sciences Inc
|
0.00 | 114.97M | 0 | -97.22M | -82.44M | -1.38 |
VRTX
Vertex Pharmaceuticals Inc
|
429.82 | 109.09B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
714.89 | 74.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
782.17 | 48.64B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.05 | 39.39B | 4.29B | 577.22M | 641.34M | 4.2086 |
ONC
Beone Medicines Ltd Adr
|
312.12 | 32.38B | 5.36B | 287.73M | 924.18M | 2.5229 |
Cassava Sciences Inc Stock (SAVA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-26 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-10-08 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2024-07-01 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2022-11-16 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2021-07-15 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2021-07-07 | Bestätigt | Maxim Group | Buy |
| 2021-04-27 | Eingeleitet | B. Riley Securities | Buy |
| 2021-02-16 | Bestätigt | H.C. Wainwright | Buy |
| 2020-10-23 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-09-23 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-05-18 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2020-05-15 | Herabstufung | Maxim Group | Buy → Hold |
| 2020-01-10 | Bestätigt | Maxim Group | Buy |
Alle ansehen
Cassava Sciences Inc Aktie (SAVA) Neueste Nachrichten
Cassava Sciences stock (US14428V1035): Alzheimer drug candidate in focus after latest data update - AD HOC NEWS
FLNA Stock Price, Quote & Chart | FILANA THERAPEUTICS INC (NASDAQ:FLNA) - ChartMill
Cassava Sciences says DOJ has closed probe into allegations around its Alzheimer’s program - MSN
Filana Therapeutics (FLNA) details 2026 meeting and equity plan vote - Stock Titan
Cassava Sciences (FLNA) Financials 2026Income Statement and Balance Sheet $FLNA - MarketBeat
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 10, 2025 in Cassava Sciences, Inc. LawsuitSAVA - ACCESS Newswire
Cassava Sciences (FLNA) Institutional Ownership 2026 $FLNA - MarketBeat
Cassava Sciences Inc Share PriceShare CFDs - FOREX.com
Cassava Sciences (NASDAQ:SAVA) Stock Price Down 0.6%Should You Sell? - MarketBeat
SAVA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Cassava Sciences, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
FLNA Stock Price, News & Analysis - Stock Titan
Filana Therapeutics Announces Publication in Epilepsia of Preclinical Simufilam Data - GlobeNewswire
Death Cross: What are the future prospects of Cassava Sciences Inc Equity WarrantPortfolio Gains Summary & Verified Chart Pattern Trade Signals - baoquankhu1.vn
FLNA|Cassava Sciences Ord Shs|Price:1.440|Chg%:0.06 - TradingKey
FLNA|Cassava Sciences Ord Shs|Price:1.440|Chg%:-0.12 - TradingKey
If You Invested $1,000 in Cassava Sciences (SAVA) - Stock Titan
Trend Report: What is the dividend yield of Cassava Sciences Inc Equity Warrant2026 Geopolitical Influence & Entry and Exit Point Strategies - baoquankhu1.vn
Aug Chart Watch: Is Cassava Sciences Inc Equity Warrant trading at a discountWeekly Market Outlook & High Accuracy Swing Trade Signals - baoquankhu1.vn
Market Leaders: Can Cassava Sciences Inc Equity Warrant maintain its current growth rate2026 Levels & Low Risk Investment Opportunities - baoquankhu1.vn
Aug Update: Is Cassava Sciences Inc Equity Warrant subject to activist investor interestWatch List & Consistent Return Investment Signals - baoquankhu1.vn
RSI Check: What is the dividend yield of Cassava Sciences IncPortfolio Performance Report & High Conviction Buy Zone Alerts - baoquankhu1.vn
SEC Moves To Set Up $40M Investor Fund In Cassava Case - Law360
Cassava Sciences Stock Rises 1.8% - National Today
Cassava Sciences (NASDAQ:SAVA) Stock Price Up 1.8%Here's What Happened - MarketBeat
RSI Check: Is Cassava Sciences Inc backed by strong institutional buying2026 PreEarnings & Fast Entry Momentum Alerts - baoquankhu1.vn
Dow Update: What is the dividend yield of Cassava Sciences Inc Equity WarrantInsider Selling & Proven Capital Preservation Tips - baoquankhu1.vn
Cassava Sciences, Inc. (FLNA) - Minichart
Energy Moves: What is Cassava Sciences Inc Equity Warrants book value per share - baoquankhu1.vn
SAVA PE Ratio & Valuation, Is SAVA Overvalued - Intellectia AI
ETF Watch: What are the future prospects of Cassava Sciences Inc Equity WarrantPortfolio Risk Report & Free Community Consensus Stock Picks - baoquankhu1.vn
Shareholders that lost money on Cassava Sciences, Inc.(SAVA) Urg - GuruFocus
Cassava Sciences, Inc. Common Stock (FLNA) Competitors - Meyka
FOMO Trade: Does Cassava Sciences Inc Equity Warrant offer margin of safety2026 Key Highlights & Expert Approved Momentum Ideas - baoquankhu1.vn
Trading Recap: Is Cassava Sciences Inc Equity Warrant subject to activist investor interest2026 Sentiment & Daily Stock Trend Watchlist - baoquankhu1.vn
Block Trades: Does Cassava Sciences Inc Equity Warrant have pricing powerMarket Sentiment Summary & Long-Term Growth Stock Strategies - baoquankhu1.vn
Cassava Sciences, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before February 10, 2025 to Discuss Your RightsSAVA - marketscreener.com
Cassava Sciences, Inc. Class Action: The Gross Law Firm Reminds Cassava Sciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 10, 2025SAVA - marketscreener.com
Filana Therapeutics, Inc.: Target Price Consensus and Analysts Recommendations | PX91 | US14817C1071 - marketscreener.com
Shareholders of Cassava Sciences, Inc. Should Contact The Gross Law Firm Before February 10, 2025 to Discuss Your RightsSAVA - marketscreener.com
Filana Therapeutics Inc (FLNA-Q) Profile - The Globe and Mail
Filana Therapeutics Inc (FLNA-Q) Stock Price and News - The Globe and Mail
Cassava Sciences, Inc. Class Action: Levi & Korsinsky Reminds Cassava Sciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 10, 2025SAVA - marketscreener.com
Filana Therapeutics, Inc.: Target Price Consensus and Analysts Recommendations | SAVA * | US14817C1071 - marketscreener.com
FLNA Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Cassava Sciences Posts Earnings, Beats Estimates - National Today
Cassava Sciences (NASDAQ:SAVA) Posts Earnings Results, Beats Estimates By $0.04 EPS - MarketBeat
Filana Therapeutics (NASDAQ: SAVA) pivots to TSC epilepsy amid FDA clinical hold - Stock Titan
Total equity of Cassava Sciences, Inc. – BMV:FLNA - TradingView
Average basic shares outstanding of Cassava Sciences, Inc. – BMV:FLNA - TradingView
Cassava Sciences, Inc. Cash Flow – BMV:FLNA - TradingView
Price to book ratio of Cassava Sciences, Inc. – BMV:FLNA - TradingView
Finanzdaten der Cassava Sciences Inc-Aktie (SAVA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Cassava Sciences Inc-Aktie (SAVA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Barry Richard | President & CEO |
Nov 20 '25 |
Buy |
2.76 |
150,000 |
414,000 |
938,060 |
| Barry Richard | President & CEO |
Nov 19 '25 |
Buy |
2.75 |
73,385 |
201,809 |
788,060 |
| Cook Robert Christopher | Chief Operating & Legal Office |
Sep 30 '25 |
Buy |
2.91 |
13,725 |
39,940 |
13,725 |
| Barry Richard | President & CEO |
Sep 22 '25 |
Buy |
2.28 |
7,172 |
16,352 |
714,675 |
| Barry Richard | President & CEO |
Sep 18 '25 |
Buy |
2.24 |
190,633 |
426,424 |
660,195 |
| Barry Richard | President & CEO |
Sep 19 '25 |
Buy |
2.29 |
47,308 |
108,319 |
707,503 |
11.97%
3.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):